Literature DB >> 12351586

Phenotypic diversity in hypertrophic cardiomyopathy.

Michael Arad1, J G Seidman, Christine E Seidman.   

Abstract

In recent years, the main focus of human genetic studies on hypertrophic cardiomyopathy (HCM) switched from discovering novel genes and defining disease-causing mutations to studies of mutation distribution in disease populations. Eventually these studies will define genotype-phenotype relationships, which may provide clues to understanding the disease process and help to select the most appropriate treatment strategy. Animal models engineered to recapitulate human disease provide a unique tool to investigate the pathogenic mechanisms and evaluate potential therapies. In this review, we present the spectrum of clinical HCM in the context of the genetic heterogeneity of this common human disease. Recent progress made in understanding molecular pathways that result in cardiac hypertrophy and the factors that modify these processes are discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12351586     DOI: 10.1093/hmg/11.20.2499

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C.

Authors:  Nicholas Swindle; Svetlana B Tikunova
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

2.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

3.  On predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

4.  A delta-sarcoglycan gene polymorphism as a risk factor for hypertrophic cardiomyopathy.

Authors:  Rosa M Ordoñez-Razo; Martín H Garrido-Garduño; Ramón A Pérez-Martínez; Victor M Ruiz; Esteban Herrera-Tepatlán; Maricela Rodríguez-Cruz; Ana L Jiménez-Vaca; Fernando Minauro-Sanmiguel; Fabio A Salamanca-Gómez
Journal:  Genet Test Mol Biomarkers       Date:  2012-04-23

5.  Functional characterization of the human α-cardiac actin mutations Y166C and M305L involved in hypertrophic cardiomyopathy.

Authors:  Mirco Müller; Antonina Joanna Mazur; Elmar Behrmann; Ralph P Diensthuber; Michael B Radke; Zheng Qu; Christoph Littwitz; Stefan Raunser; Cora-Ann Schoenenberger; Dietmar J Manstein; Hans Georg Mannherz
Journal:  Cell Mol Life Sci       Date:  2012-05-29       Impact factor: 9.261

Review 6.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

7.  Navigating the road to personalized medicine: can we believe?

Authors:  Gideon M Hirschfield; Christopher I Amos; Katherine A Siminovitch
Journal:  CMAJ       Date:  2010-04-06       Impact factor: 8.262

8.  Image-guided cardiovascular functional genomics: finding the needle in the haystack.

Authors:  Sharon Cresci; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

Review 9.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

10.  Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.

Authors:  Mark Luedde; Ulrich Flögel; Maike Knorr; Christina Grundt; Hans-Joerg Hippe; Benedikt Brors; Derk Frank; Uta Haselmann; Claude Antony; Mirko Voelkers; Juergen Schrader; Patrick Most; Bjoern Lemmer; Hugo A Katus; Norbert Frey
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.